Stanford Health Care, based in Palo Alto, Calif., is testing a new tool from Microsoft designed to ease the burden of preparing complex cancer cases for tumor board meetings. The technology — a ...

While patient clinical data and metadata are now being collected ... process of creating drug candidates before any clinical testing can be considered. MTPC has found a powerful use for AI in ...

The US Food and Drug Administration has given marketing clearance to a blood test to help diagnose Alzheimer’s disease, ...

Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe ...

The presentation titled " Utilization of Proteomic Testing in Pulmonary Nodule Risk Stratification at a Safety-Net Hospital: ...

The team established reference ranges for each gene based on control data. To assess clinical performance, the team evaluated ...

Regeneron bids for 23andMe for a discounted price of $256 million. The testing firm was once valued at $3.5 billion.